Recent New Development and Advances in Diagnosis and Treatment
By Dr Lisa Bodei (Itay) and Dr Irvin Modlin (USA)
Chair: Dr Liau Kui Hin
Accurate Dosimetry for Peptide Receptor Radionuclide TherapyDr Lisa BodeiThe biologic basis for receptor radionuclide diagnosis and therapy is the receptor-mediated internalization and intracellular retention of a radiolabeled peptide. An important factor in the success of this treatment and the avoidance of toxicity is delivery of the optimal dose in view of patient's body mass, tumor burdon and the absorbed dose in specific organs.
Multi-Transcript Analysis - A Better Marker for Neuroendocrine Tumors
Dr Irvin Modlin
There are no highly-specific biomarkers to detect neuroendocrine tumors. Measurement of the neuroendocrine secretory peptide Chromogranin A (CgA) is used, but it is a single value, it is non-specific and the assay data are highly variable. To better facilitate tumor detection, Dr Modlin's team developed a multi-transcript molecular signature for blood analysis, based on a large database of tissue samples from NET patients. This molecular diagnostic process, now being marketed by Wren Labs as the 'NETest', is significantly more accurate than the CgA assay, is less vulnerable to false-positives, and shows promise as a screening test for early detection of neuroendocrine cancer.
Additional Presentation on Diagnostic Imaging
Dr Lisa Bodei